Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.

ABSTRACT:

Background

Stereotactic ablative body radiotherapy (SABR) is one of the treatment options for oligometastatic renal cell carcinoma (RCC) but is limited by a lack of data to evaluate high-dose SABR to all/multiple sites.

Objective

This study retrospectively investigated the efficacy and prognostic factors of high-dose SABR for oligometastatic RCC patients.

Design, setting, and participants

Patients with oligometastatic RCC on systemic therapy were retrospectively collected.

Intervention(s)

All patients were treated with SABR (40-50 Gy/5 fractions) for small tumors or partial-SABR (tumor center boosted with 6-8 Gy/3-5 fractions with 50-60 Gy/20-25 fractions to the whole tumor volume) for bulky tumors or tumors adjacent to critical organs.

Outcome measurements

SUBMITTER: Ma MW 

PROVIDER: S-EPMC9600736 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature